Zymeworks Inc (NYSE:ZYME) was the recipient of some unusual options trading on Thursday. Investors acquired 2,611 call options on the stock. This represents an increase of 520% compared to the average volume of 421 call options.

Several equities research analysts have recently weighed in on ZYME shares. Citigroup upped their price target on Zymeworks from $49.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, June 2nd. TheStreet lowered Zymeworks from a “c” rating to a “d+” rating in a report on Thursday, March 26th. Raymond James set a $60.00 price objective on Zymeworks and gave the stock a “strong-buy” rating in a report on Thursday. Paradigm Capital reissued a “buy” rating and set a $51.00 price objective on shares of Zymeworks in a report on Friday, May 8th. Finally, HC Wainwright cut their price objective on Zymeworks from $60.00 to $54.00 and set a “buy” rating for the company in a report on Thursday. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $50.25.

NYSE:ZYME opened at $33.19 on Friday. The firm has a market cap of $1.70 billion, a PE ratio of -8.53 and a beta of 1.15. Zymeworks has a fifty-two week low of $20.33 and a fifty-two week high of $52.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.92 and a current ratio of 6.92. The business has a 50 day moving average price of $36.81 and a 200-day moving average price of $39.26.

Zymeworks (NYSE:ZYME) last announced its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.51. The firm had revenue of $8.27 million for the quarter, compared to analyst estimates of $7.78 million. Zymeworks had a negative net margin of 629.37% and a negative return on equity of 46.17%. Research analysts predict that Zymeworks will post -3.45 EPS for the current year.

A number of large investors have recently bought and sold shares of ZYME. FMR LLC boosted its stake in Zymeworks by 331.4% during the first quarter. FMR LLC now owns 2,401,897 shares of the company’s stock worth $38,863,000 after acquiring an additional 1,845,142 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Zymeworks by 32.4% during the fourth quarter. Victory Capital Management Inc. now owns 259,543 shares of the company’s stock worth $11,799,000 after acquiring an additional 63,553 shares in the last quarter. TD Asset Management Inc. boosted its stake in Zymeworks by 10.8% during the fourth quarter. TD Asset Management Inc. now owns 33,915 shares of the company’s stock worth $1,542,000 after acquiring an additional 3,300 shares in the last quarter. Citigroup Inc. bought a new stake in Zymeworks during the fourth quarter worth about $79,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in Zymeworks by 75.1% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 50,684 shares of the company’s stock worth $2,304,000 after acquiring an additional 21,730 shares in the last quarter. 72.00% of the stock is currently owned by institutional investors and hedge funds.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.

See Also: Options Trading

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.